Home Health M&A Firms and Acquisition Advisors: 2026 Guide

Home Health M&A Firms and Acquisition Advisors: How to Choose an M&A Advisor for a Home Health Agency in 2026

Home health M&A firms and acquisition advisors sell, recapitalize and buy Medicare-certified home health agencies. This guide shows how to choose an M&A advisor for a home health agency in 2026: what a specialist does that a generalist bank or business broker does not, which CMS rules decide whether your deal can close, what advisors charge, and the questions to ask before you sign an engagement letter.

Quick answer: Hire an advisor who has recently closed Medicare-certified home health deals, checks your dates against the CMS 36-month rule and the May 13, 2026 enrollment moratorium before going to market, and puts every fee in writing. The most common success fee on a $10 million deal was 4.0% in the Firmex Global M&A Fee Guide 2024-25.

What home health acquisition advisors do

An M&A advisor runs a home health sale from first valuation to closing. The work splits into four jobs.

  1. Recast the earnings. The advisor rebuilds your profit and loss into adjusted EBITDA that a buyer’s diligence team will accept: owner pay normalized, one-time costs removed, and Medicare revenue tied back to claims data. Many owners commission a sell-side quality of earnings report at this stage.
  2. Clear the regulatory file. Survey history, Care Compare star ratings, OASIS accuracy, billing audits, state licensure, and the dates of your Medicare enrollment and every change in majority ownership. In home health these items decide whether a deal can close, not only its price.
  3. Find and run the buyers. A short list of strategic operators, private equity platforms and add-on buyers active in your state, contacted under NDA, with a confidential information memorandum and a deadline for written offers.
  4. Negotiate and close. The letter of intent, working capital target, escrow, the Medicare enrollment filing on Form CMS-855A, the state license transfer, and the purchase agreement terms that split regulatory risk between you and the buyer.
Conference room for the sell-side process run by home health acquisition advisors

A generalist can handle the first and last jobs. The middle two are where home health experience shows, because a buyer who finds a survey or enrollment timing problem in diligence will cut the price or walk away. Our guide to selling a home health business covers preparation.

Specialist home health advisors vs generalist banks and business brokers

Three kinds of firms pitch home health owners. Which fits depends on your size, your realistic buyers and your regulatory file.

Factor Specialist home-based care advisor Generalist investment bank Business broker
Buyer access Regular contact with the operators and PE platforms that buy agencies Strong private equity coverage; may know fewer regional home health operators Listing sites, local operators and individual buyers
Regulatory depth 36-month rule, CMS-855A filings, survey and star-rating diligence Varies by team; often relies on outside healthcare counsel Usually limited; the buyer’s counsel drives regulatory diligence
Process Targeted outreach to a curated buyer list, competing written offers Broad competitive auction Public or semi-public listing, offers handled as they arrive
Fee structure Success fee on a sliding scale, sometimes with a work fee Retainer or monthly fee plus a success fee with a minimum Commission on the sale price, set in the listing agreement

A business broker can suit a very small agency likely to sell to an individual or a local operator. Once a private equity platform or multi-state operator is a realistic buyer, competing written offers let you negotiate price and terms against each other instead of on one buyer’s timetable. See our M&A advisor vs business broker comparison.

Specialist home health M&A firms include Mertz Taggart, whose quarterly M&A report is cited below, and Stoneridge Partners and The Braff Group, which both list home health as a practice area on their own sites. Interview at least two specialists and one generalist, and compare buyer lists, not just fee quotes.

CT Acquisitions is an M&A advisory firm for founder-owned businesses. We work both sides of the table: on the sell side we run confidential sales and recapitalizations for owners, and on the buy side we find, vet and negotiate acquisitions for buyers. Our network includes 500+ active buyers, from private equity firms and family offices to search funders and strategic acquirers. Read how we run a mandate on our M&A advisory page.

The home health M&A market in 2026: deals and data

Home-based care deal volume slowed in the second quarter of 2026. Mertz Taggart’s Q2 2026 Home-Based Care M&A Report counted 16 closed transactions, down from 27 in Q1 2026 and 29 in Q2 2025. Hospice and home care had 8 deals each, and skilled home health had 6.

The same report split the quarter’s buyers into 6 new private equity platforms, 4 sponsor-backed add-ons, 1 public company and 5 strategic or independent buyers. Managing partner Cory Mertz named fraud takedowns, the hospice 36-month rule, the new enrollment moratorium and enhanced oversight as the reasons deals were harder to get across the line.

Deal Segment Value Status Source
UnitedHealth Group (Optum) acquires Amedisys Home health and hospice $3.3 billion Closed August 14, 2025, after a DOJ settlement requiring 164 home health and hospice locations in 19 states to be divested U.S. Department of Justice; Hospice News
Kinderhook Industries takes Enhabit private Home health and hospice $1.1 billion ($13.80 per share) Announced February 2026, closed May 2026 Mertz Taggart; Healthcare Dive
General Atlantic acquires TEAM Services Group from Alpine Investors Home care About $3 billion Closed in Q2 2026 Mertz Taggart
Ares Management and DaVita invest in Elara Caring Home-based care Not disclosed Announced February 2026, expected to close later in 2026 DaVita newsroom
Addus HomeCare acquires Gentiva’s personal care business Personal care $350 million Closed December 2024 Addus SEC filing; Hospice News
Financial binder showing EBITDA multiples for home health acquisition advisors

Two points from these deals matter for a smaller owner. First, the Enhabit price worked out to 10.2x EBITDA on $108 million of EBITDA, according to Mertz Taggart. That is a take-private of a public company, not a benchmark for a single-branch agency, and an advisor who quotes it as your multiple is selling, not advising. Second, the Amedisys settlement shows how closely the Department of Justice reviews overlapping home health footprints. Ask each advisor which buyers are active in your counties and which already own agencies nearby.

For what drives the price of a smaller agency, see our home health business valuation guide and the 2026 home health PE roll-up tracker.

CMS rules that decide whether your deal can close

In home health, federal enrollment rules can stop a signed deal. Four rules matter most in 2026.

The 36-month rule

Under 42 CFR 424.550(b), if a home health agency or hospice has a change in majority ownership by sale within 36 months after its initial Medicare enrollment or its most recent change in majority ownership, the provider agreement and Medicare billing privileges do not convey to the new owner. The buyer has to enroll as a new provider and go through a state survey or accreditation. The regulation lists exceptions, including an agency that has filed two consecutive years of full cost reports, an internal corporate restructuring, a change in business structure where the owners stay the same, and the death of an owner.

Your advisor should pull your initial enrollment date and every ownership change date before a single buyer sees your name. If you are inside the window and no exception applies, the deal has to be timed after it or structured around it.

The 2026 nationwide enrollment moratorium

CMS imposed a six-month nationwide moratorium on new Medicare enrollments for home health agencies and hospices effective May 13, 2026. The CMS moratorium Q&As, last revised July 9, 2026, say it covers initial applications and non-exempt changes in majority ownership under 424.550(b), and that such applications submitted after the start date will be denied. CMS also says enrolled providers can still acquire and merge with other enrolled providers, provided no change in majority ownership requires a new enrollment and no new locations are added.

Six months from its start, the moratorium runs through November 13, 2026 unless CMS extends it, and the same CMS Q&As say moratoria can be extended in further six-month blocks by Federal Register notice. In practice, a sale of an agency outside its 36-month window can generally proceed, a sale that would trigger a new enrollment cannot proceed until the moratorium lifts, and a buyer cannot add your site as a new branch on its own enrollment.

2026 and 2027 Medicare payment rates

The CMS fact sheet for the CY 2026 home health final rule estimates that Medicare payments to home health agencies fall 1.3%, or $220 million, in 2026 compared with 2025: a 2.4% payment update offset by a 0.9% permanent and a 2.7% temporary adjustment tied to the Patient-Driven Groupings Model (PDGM).

For 2027, the CMS proposed rule (CMS-1844-P, released July 1, 2026) would raise aggregate payments 2.4%, or $420 million, while keeping a 3% temporary cut, according to the American Hospital Association’s summary. It also proposes making Medicare enrollment revocations retroactive to the date of the non-compliant conduct, according to a Holland & Knight analysis. The final rule had not been published as of early October 2026. Your advisor should show the effect on your EBITDA before a buyer does.

Value-based purchasing

Under the expanded Home Health Value-Based Purchasing Model, which covers Medicare-certified agencies in all 50 states, CMS applies a payment adjustment between minus 5% and plus 5% based on quality performance, according to the CMS Innovation Center. The first payment year was 2025. A weak score becomes a diligence question.

What home health M&A advisors charge

No regulator sets M&A advisory fees, so the best public benchmark is survey data. The Firmex Global M&A Fee Guide 2024-25, based on 456 middle-market advisors, found these structures:

Deal size Most common effective success fee (Firmex 2024-25) Fee in dollars
$5 million 4.8% $240,000
$10 million 4.0% $400,000
$20 million 3.4% $680,000
$50 million 2.7% $1,350,000
$100 million 2.0% $2,000,000

These are global figures; Firmex found European fees ran 0.4 to 1.1 points below North America, so U.S. quotes can sit at or above the table. For a fuller breakdown, see our 2026 M&A advisor fees guide.

How CT Acquisitions is paid depends on the mandate. When a buyer from our network approaches you through a buy-side search, you pay no fee. When you hire us to run a sell-side process, we are paid on success, at closing. You will know the terms in writing before any work starts.

Worked example: fees on a $10 million agency sale

This is an illustration, not a quote. Assume an agency sells for $10 million and the advisor charged a $7,500 monthly work fee for six months, credited against the success fee at closing.

Fee structure Success fee Effective rate Work fees already paid Balance due at closing
Classic Lehman $200,000 2.0% $45,000 $155,000
Double Lehman $400,000 4.0% $45,000 $355,000
Most common rate at $10 million (Firmex) $400,000 4.0% $45,000 $355,000

The Classic Lehman math is 5% of the first $1 million ($50,000), 4% of the second ($40,000), 3% of the third ($30,000), 2% of the fourth ($20,000) and 1% of the remaining $6 million ($60,000), for $200,000. Double Lehman doubles each step: $100,000, $80,000, $60,000, $40,000 and 2% of $6 million ($120,000), for $400,000. The credit changes when you pay, not how much.

The bigger number is price. If a competitive process lifted the sale from $10 million to $11 million, the extra $1 million would be five times the entire Classic Lehman fee. Ask how the fee applies to an earnout or seller note; Firmex found more firms in 2024 agreed to delay fees when the seller is paid over time.

How to choose an M&A advisor for a home health agency: 7 steps

  1. Check your own dates first. Pull your Medicare enrollment date and every change in majority ownership so you know where you stand on the 36-month rule and the moratorium before anyone pitches you.
  2. Shortlist by segment. Ask for closed deals in your exact category: Medicare-certified home health, hospice or non-medical home care. Each has a different buyer pool.
  3. Ask for named buyers, not a database size. Request the 10 buyers the advisor would call first for your agency and why each one fits your state and payer mix.
  4. Test regulatory fluency. Ask how they would handle a CMS-855A filing, a recent survey deficiency, or a sale during the moratorium. Vague answers are a warning sign.
  5. Get the full fee in writing. Success fee formula, minimum fee, work fees and whether they are credited, expenses, the tail period after the engagement ends, and how earnouts and seller notes are treated.
  6. Ask about conflicts. Many firms also run buy-side searches. Ask what happens if one of their buy-side clients bids for your agency.
  7. Call two recent sellers. Ask what the first offer was, what the final price was, and what surprised them in diligence.

Questions to ask home health acquisition advisors in the first meeting

Frequently Asked Questions

What do home health acquisition advisors do?

They run the sale, recapitalization or purchase of a home health agency: recasting earnings, preparing regulatory diligence such as survey history and Medicare enrollment dates, contacting buyers, negotiating the letter of intent and purchase agreement, and coordinating the CMS-855A enrollment filing at closing.

How much does an M&A advisor charge to sell a home health agency?

Most charge a success fee at closing. In the Firmex Global M&A Fee Guide 2024-25, the most common effective success fee was 4.8% on a $5 million deal, 4.0% on a $10 million deal and 2.0% on a $100 million deal. Many also charge a monthly work fee, most often $5,000 to $10,000.

Can I sell my home health agency during the 2026 CMS enrollment moratorium?

Often, yes. CMS says enrolled providers can still be acquired if no change in majority ownership requires a new enrollment and no new locations are added. A sale inside the 36-month rule without an exception needs a new enrollment, which is denied while the moratorium runs. It began on May 13, 2026 and runs through November 13, 2026 unless CMS extends it.

What is the 36-month rule for home health agencies?

Under 42 CFR 424.550(b), if majority ownership of a home health agency or hospice changes by sale within 36 months of its initial Medicare enrollment or its last change in majority ownership, the provider agreement and billing privileges do not transfer to the buyer unless an exception applies. The buyer must enroll as a new provider.

Should I use a business broker or an M&A advisor for a home health agency?

A broker can suit a very small agency likely to sell to an individual or a local operator. If private equity platforms or multi-state operators are realistic buyers, an M&A advisor who runs a competitive process and knows Medicare enrollment rules is usually the better fit.

What is the difference between a home health and a home care M&A firm?

Often it is the same firm, but the deals differ. Home health agencies are Medicare-certified, so buyers focus on star ratings, surveys and enrollment rules. Non-medical home care is paid by private pay clients, Medicaid and long-term care insurance, so buyers focus on caregiver retention, payer mix and state licensing.

Do home health acquisition advisors also represent buyers?

Many do, including CT Acquisitions, which works on both the sell side and the buy side. Ask in writing how any advisor handles a conflict if one of its buy-side clients bids for your agency.

Sources and method

Every figure on this page is attributed in the sentence where it appears and was checked against the named source on October 5, 2026: CMS, the eCFR, the Department of Justice, Mertz Taggart, Firmex and the trade press reports named in the deal table.

This guide is general information, not legal, tax or investment advice. Confirm the moratorium status and the CY 2027 final rule with healthcare counsel before you sign. CT Acquisitions is based in Sheridan, Wyoming.